Compass Pathways PLC (CMPS) intrinsic value & 10-year financials

Compass Pathways PLC (CMPS) has no Graham intrinsic value right now because the formula needs positive earnings.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$10.75
Market cap
$1.0B
Revenue (FY2025)
—
ROIC (10-yr avg)
-260.8%
Free cash flow (FY2025)
—

CMPS 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 — -$287.9M -$3.08 — — 237.6%
FY2024 — -$155.1M -$2.30 — — -633.4%
FY2023 — -$118.5M -$2.32 -$97.4M — -366.7%
FY2022 — -$91.5M -$2.16 -$106.0M — -432.6%
FY2021 — -$71.7M -$1.79 -$68.1M — -663.2%
FY2020 — -$60.3M -$3.55 -$41.5M — -61.9%
FY2019 — -$19.6M -$2.62 -$18.0M — 94.6%
FY2018 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

COMPASS Pathways plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

COMPASS Pathways plc has historically struggled to out-earn its cost of capital, averaging just -3.7% ROIC.

COMPASS Pathways plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

COMPASS Pathways plc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

CMPS stock: frequently asked questions

What is the intrinsic value of Compass Pathways PLC (CMPS) stock?

Graham's formula only works with positive earnings. Compass Pathways PLC reported diluted EPS of -$3.08 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

What is CMPS's return on invested capital?

Average ROIC over the last 8 fiscal years was -260.8%, and average return on equity was -108.5%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this CMPS data come from?

From Compass Pathways PLC's annual 10-K filings on SEC EDGAR, most recently filed Aug 5, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks